

Ref. No.: WOCK/SEC/SE/2024-25/011

15th May, 2024

BSE Limited Corporate Relations Department P J Towers, Dalal Street Mumbai - 400 001 <u>Scrip Code: 532300</u>	National Stock Exchange of India Limited Exchange Plaza Bandra Kurla Complex, Bandra (E), Mumbai - 400 051 <u>NSE Symbol: WOCKPHARMA</u>
---	---

Sub: Statement on Deviation or Variation of funds raised through Qualified Institutions Placement for the quarter ended 31st March, 2024

Dear Sir/Madam,

Pursuant to Regulation 32(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD1/162/2019 dated December 24, 2019, we hereby confirm that there has been no deviation in the utilization of Issue proceeds from the objects as stated in the Placement Document dated 26th March 2024 for Qualified Institutions Placement (QIP).

The 'Statement of deviation' in the prescribed format, confirming Nil deviation, duly reviewed by the Audit Committee is attached herewith as '**Annexure A**'.

Kindly take the above information on record.

Thanking you,

For **Wockhardt Limited**

Rashmi Mamtura
Company Secretary

Encls: A/a.



Annexure A

Statement of Deviation / Variation in utilisation of funds raised

Name of the Company	Wockhardt Limited
Mode of Fund Raising	Qualified Institutions Placement
Date of Raising Funds	26-03-2024
Amount Raised (in Rs. Crores)	480.04
Report filed for Quarter ended	31-03-2024
Monitoring Agency	Applicable
Monitoring Agency Name, if applicable	CRISIL RATINGS LIMITED
Is there a Deviation / Variation in use of funds raised	No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	NA
If Yes, Date of shareholder Approval	NA
Explanation for the Deviation / Variation	NA
Comments of the Audit Committee after review	No Deviation
Comments of the auditors, if any	NA

Objects for which funds have been raised and where there has been a deviation, in the following table

Original Object	Modified Object, if any	Original Allocation (Rs. in crore)	Modified allocation, if any	Funds Utilised (Rs. in crore)	Amount of Deviation/ Variation for the quarter according to applicable object	Remarks if any
Repayment and / or pre – payment, in full or part, of certain borrowings availed by our Company	No	110.00	NIL	10.00	NIL	NA
Funding of costs related to the clinical trials and research and development undertaken by the Company and/ or Wockhardt Bio AG, one of the Subsidiaries of the Company	No	210.00	NIL	NIL	NIL	NA

Funding working capital requirements of the Company	No	115.00	NIL	NIL	NIL	NA
General corporate purposes	No	27.87	NIL	NIL	NIL	NA
Total Net Proceeds*		462.87				

* Excluding estimated 'Issue related expenses'.

For Wockhardt Ltd

Name of the Signatory: Rashmi Mamtura
Designation: Company Secretary & Compliance Officer

